Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 18:4:9-17.
doi: 10.2147/dddt.s8410.

Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal

Chaouki K Khoury  1 , James R Couch
Affiliations
Review

Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal

Chaouki K Khoury et al. Drug Des Devel Ther. .

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen and naproxen sodium, are effective yet nonspecific analgesic and anti-inflammatory drugs, which work for a variety of pain and inflammatory syndromes, including migraine. In migraine, their analgesic effect helps relieve the headache, while their anti-inflammatory effect decreases the neurogenic inflammation in the trigeminal ganglion. This is the hypothesized mechanism by which they prevent the development of central sensitization. Triptans, including sumatriptan, work early in the migraine process at the trigeminovascular unit as agonists of the serotonin receptors (5-HT receptors) 1B and 1D. They block vasoconstriction and block transmission of signals to the trigeminal nucleus and thus prevent peripheral sensitization. Therefore, combining these two drugs is an attractive modality for the abortive treatment of migraine. Sumatriptan-naproxen fixed combination tablet (Treximet [sumatriptan-naproxen]) proves to be an effective and well tolerated drug that combines these two mechanisms; yet is far from being the ultimate in migraine abortive therapy, and further research remains essential.

Keywords: Treximet®; migraine; sumatriptan-naproxen; treatment.

PubMed Disclaimer

References

    1. Rasmussen BK. Epidemiology of headache. Cephalalgia. 2001;21(7):774–777. - PubMed
    1. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;279(5):381–383. - PubMed
    1. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993;43(6 Supplement 3):S6–10. - PubMed
    1. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999;53(3):537–542. - PubMed
    1. Lipton, et al. Headaches and face pain as a manisfestation of Munchausen Syndrome. Headache. 1999;39(1):45–50. - PubMed

MeSH terms